CH648023A5 - 4'-(9-acridinylamino)methansulfon-m-anisidid-gluconat und dieses enthaltende mischungen. - Google Patents
4'-(9-acridinylamino)methansulfon-m-anisidid-gluconat und dieses enthaltende mischungen. Download PDFInfo
- Publication number
- CH648023A5 CH648023A5 CH484/81A CH48481A CH648023A5 CH 648023 A5 CH648023 A5 CH 648023A5 CH 484/81 A CH484/81 A CH 484/81A CH 48481 A CH48481 A CH 48481A CH 648023 A5 CH648023 A5 CH 648023A5
- Authority
- CH
- Switzerland
- Prior art keywords
- anisidide
- acridinylamino
- methanesulfone
- organic compound
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 36
- -1 9-ACRIDINYLAMINO Chemical class 0.000 title claims description 14
- 229940050410 gluconate Drugs 0.000 title 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 56
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 43
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 29
- 235000012208 gluconic acid Nutrition 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000174 gluconic acid Substances 0.000 claims description 28
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 27
- 229960003681 gluconolactone Drugs 0.000 claims description 27
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 25
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 150000002894 organic compounds Chemical class 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008365 aqueous carrier Substances 0.000 claims description 5
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 2
- 229950006191 gluconic acid Drugs 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 19
- 239000000047 product Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940113088 dimethylacetamide Drugs 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XXNAQBNJPZNRSZ-UHFFFAOYSA-N n-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide;2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OCC(O)C(O)C(O)C(O)C(O)=O.COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XXNAQBNJPZNRSZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11480980A | 1980-01-24 | 1980-01-24 | |
| US06/194,350 US4322424A (en) | 1980-01-24 | 1980-10-17 | Crystalline glucoconate salt of m-AMSA and compositions containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH648023A5 true CH648023A5 (de) | 1985-02-28 |
Family
ID=26812557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH484/81A CH648023A5 (de) | 1980-01-24 | 1981-01-26 | 4'-(9-acridinylamino)methansulfon-m-anisidid-gluconat und dieses enthaltende mischungen. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4322424A (en, 2012) |
| AT (1) | AT380474B (en, 2012) |
| AU (1) | AU543758B2 (en, 2012) |
| CA (1) | CA1252103A (en, 2012) |
| CH (1) | CH648023A5 (en, 2012) |
| DE (1) | DE3102026A1 (en, 2012) |
| DK (1) | DK29781A (en, 2012) |
| FI (1) | FI79840C (en, 2012) |
| FR (1) | FR2474493B1 (en, 2012) |
| GB (1) | GB2068729B (en, 2012) |
| GR (1) | GR82326B (en, 2012) |
| IE (1) | IE50884B1 (en, 2012) |
| IT (1) | IT1170638B (en, 2012) |
| LU (1) | LU83081A1 (en, 2012) |
| NL (1) | NL8100292A (en, 2012) |
| SE (1) | SE453497B (en, 2012) |
| YU (1) | YU42552B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU186383B (en) * | 1981-02-27 | 1985-07-29 | Biogal Gyogyszergyar | Process for producing new citostatic amni-acridie-alpha, beta-bracket-d-bracket closed, or aracket-l-bracket closed-n-glycoside derivatives and salts |
| US4575509A (en) * | 1983-01-31 | 1986-03-11 | Bristol-Myers Company | Water-soluble formulations of m-AMSA with pyroglutamic acid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1674923A (en) * | 1924-04-12 | 1928-06-26 | Schnorf Carl | Process for the production of carbohydrate-acridine compounds and solutions thereof |
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| US4258191A (en) * | 1979-03-29 | 1981-03-24 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Multi-step process for the production of methanesulfon-m-anisidide, 4'-(9-acridinylamino)- |
| AU534608B2 (en) * | 1979-09-14 | 1984-02-09 | Warner-Lambert Corporation | Compounds having antitumour properties |
| ZA811304B (en) * | 1980-03-11 | 1982-06-30 | Warner Lambert Co | Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide |
-
1980
- 1980-10-17 US US06/194,350 patent/US4322424A/en not_active Expired - Lifetime
-
1981
- 1981-01-20 YU YU145/81A patent/YU42552B/xx unknown
- 1981-01-21 SE SE8100341A patent/SE453497B/sv not_active IP Right Cessation
- 1981-01-21 IT IT47604/81A patent/IT1170638B/it active
- 1981-01-21 NL NL8100292A patent/NL8100292A/nl not_active Application Discontinuation
- 1981-01-21 AU AU66512/81A patent/AU543758B2/en not_active Ceased
- 1981-01-22 CA CA000369109A patent/CA1252103A/en not_active Expired
- 1981-01-22 DK DK29781A patent/DK29781A/da not_active Application Discontinuation
- 1981-01-22 DE DE19813102026 patent/DE3102026A1/de active Granted
- 1981-01-22 FI FI810180A patent/FI79840C/fi not_active IP Right Cessation
- 1981-01-23 GB GB8102175A patent/GB2068729B/en not_active Expired
- 1981-01-23 GR GR63955A patent/GR82326B/el unknown
- 1981-01-23 IE IE119/81A patent/IE50884B1/en unknown
- 1981-01-23 LU LU83081A patent/LU83081A1/fr unknown
- 1981-01-23 FR FR8101233A patent/FR2474493B1/fr not_active Expired
- 1981-01-26 AT AT0032681A patent/AT380474B/de not_active IP Right Cessation
- 1981-01-26 CH CH484/81A patent/CH648023A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3102026A1 (de) | 1982-03-04 |
| GB2068729A (en) | 1981-08-19 |
| AU543758B2 (en) | 1985-05-02 |
| FI79840C (fi) | 1990-03-12 |
| CA1252103A (en) | 1989-04-04 |
| DE3102026C2 (en, 2012) | 1990-05-31 |
| IE810119L (en) | 1981-07-24 |
| AU6651281A (en) | 1981-07-30 |
| YU42552B (en) | 1988-10-31 |
| DK29781A (da) | 1981-07-25 |
| FR2474493B1 (fr) | 1985-12-13 |
| NL8100292A (nl) | 1981-08-17 |
| SE453497B (sv) | 1988-02-08 |
| GB2068729B (en) | 1983-10-19 |
| IT8147604A0 (it) | 1981-01-21 |
| AT380474B (de) | 1986-05-26 |
| GR82326B (en, 2012) | 1984-12-13 |
| FI79840B (fi) | 1989-11-30 |
| US4322424A (en) | 1982-03-30 |
| FR2474493A1 (fr) | 1981-07-31 |
| FI810180L (fi) | 1981-07-25 |
| IT1170638B (it) | 1987-06-03 |
| SE8100341L (sv) | 1981-07-25 |
| ATA32681A (de) | 1985-10-15 |
| LU83081A1 (fr) | 1981-09-10 |
| IE50884B1 (en) | 1986-08-06 |
| YU14581A (en) | 1983-06-30 |
| IT8147604A1 (it) | 1982-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0806955B1 (de) | Enrofloxacin-injektions- oder infusionslösungen | |
| DE60001687T2 (de) | Trovafloxacin enhaltende Suspensionen zur oralen Anwendung | |
| DE1802394C2 (de) | Arzneimittel mit antihypertensiver Wirkung, die [(2,6-Dichlorbenzyliden)-amino]-guanidin oder ein Säureadditionssalz davon enthalten | |
| DE68903814T2 (de) | Etoposid-loesungen. | |
| DE69313640T2 (de) | Zink-tranexamat derivat | |
| DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
| DE3119510C2 (en, 2012) | ||
| CH642261A5 (de) | Arzneipraeparat auf der basis eines salzes der acetylsalicylsaeure und einer basischen aminosaeure und verfahren zu seiner herstellung. | |
| DE69808793T2 (de) | Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung | |
| DE69016087T2 (de) | Stabile Lösungen von Rebeccamycinderivaten sowie deren Herstellung. | |
| EP0091114B1 (de) | Pharmazeutisch wirksame organische Germaniumverbindungen | |
| CH648023A5 (de) | 4'-(9-acridinylamino)methansulfon-m-anisidid-gluconat und dieses enthaltende mischungen. | |
| DE69231098T2 (de) | Lyophilisierte zusammensetzung, die s(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis(2,6-piperazindion)enthält | |
| EP0061654B1 (de) | Vincamin-cyclamat, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel | |
| DE2318784A1 (de) | N-(2,4-dihydroxybenzoyl)-4-aminosalizylsaeure | |
| DE3044736C2 (en, 2012) | ||
| DE3843059A1 (de) | Waessrige formulierungen, die ein piperidinylcyclopentylheptensaeure-derivat enthalten | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE2307795C3 (de) | 11 beta 17alpha, 21 Trihydroxy-6 | |
| DE2511852A1 (de) | Neue breitspektrum-antibiotika | |
| DE1620177B2 (de) | N-(2-Hydroxyäthyl) -piperazinocarboxymethyl-te tr acy elin, dessen pharmakologisch verwendbaren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2901629A1 (de) | 4-pyrimidylsulfide, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und verwendung | |
| DE69000268T2 (de) | Stabilisiertes antitumormittel. | |
| DE3901508C2 (de) | Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form | |
| AT381024B (de) | Verfahren zur herstellung eines pharmazeutischen mittels zur rekonstitution mit wasser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |